United States Needle Free Injections Market Outlook to 2023
July 2017
82
About the Report
About the Report
United States Needle Free Injections Market Outlook to 2023
Summary
GlobalData's new report, "United States Needle Free Injections Market Outlook to 2023", provides key market data on the United States Needle Free Injections market. The report provides value, in millions of US dollars, volume (in units) and and average prices (USD) for Needle Free Injections.
The report also provides company shares and distribution shares data for each of these market segments, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.
Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.
Scope
Market size and company share data for Needle Free Injections.
Annualized market revenues (USD million) and volume (units) data for each of the market segments. Data is provided from 2009 to 2016 and forecast to 2023.
2016 company shares and distribution shares data for each of the market segments.
Global corporate-level profiles of key companies operating within the United States Needle Free Injections market.
Key players covered include INJEX-Equidyne Systems, Bioject Medical Technologies Inc and Antares Pharma Inc.
Reasons to buy
Develop business strategies by identifying the key market segments poised for strong growth in the future.
Develop market-entry and market expansion strategies.
Design competition strategies by identifying who-stands-where in the market.
Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
What are the key distribution channels and what's the most preferred mode of product distribution-Identify, understand and capitalize.
Products
Products
Drug Delivery Devices, Central Venous Catheters, Needle Free Injections, Infusion Systems, Metered Dose Inhaler Devices, Value (USD), Volume (units), Revenues, Historic Revenues, Forecast Revenues, Average Price, Company Share, Distribution Share by Revenue, Company Share by Revenue, Pipeline Products, News, Deals, Key Companies, GlaxoSmithKline Plc, AstraZeneca Plc, Boehringer Ingelheim GmbH, Pfizer Inc, Merck & Co Inc, Sunovion Pharmaceuticals Inc, Teva Pharmaceutical Industries Ltd, INJEX-Equidyne Systems, Bioject Medical Technologies Inc , Antares Pharma Inc, PharmaJet Inc, MK Global Co., The European Pharma Group, Hospira Inc, Becton Dickinson and Co, Baxter International Inc, Fresenius Kabi AG, Medtronic plc, B. Braun Melsungen AG, Terumo Corp, Smiths Medical, Nipro Corp, JMS Co Ltd
Companies
INJEX-Equidyne Systems
Bioject Medical Technologies Inc
Antares Pharma Inc
PharmaJet Inc
MK Global Co.
Table of Contents
Table of Contents
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 5
2 Introduction 6
2.1 What Is This Report About? 6
2.2 Needle Free Injections Market Segmentation 6
2.3 Definitions of Markets Covered in the Report 7
3 Needle Free Injections Market, United States 8
3.1 Needle Free Injections Market, United States, Revenue ($m), 2009-2016 8
3.2 Needle Free Injections Market, United States, Revenue ($m), 2016-2023 9
3.3 Needle Free Injections Market, United States, Volume (Units), 2009-2016 10
3.4 Needle Free Injections Market, United States, Volume (Units), 2016-2023 11
3.5 Needle Free Injections Market, United States, Average Price ($), 2009-2023 12
3.6 Needle Free Injections Market, United States, Distribution Share by Revenue ($m), 2015-2016 13
3.7 Needle Free Injections Market, United States, Company Share by Revenue ($m), 2016 14
4 Overview of Key Companies in United States, Needle Free Injections Market 16
4.1 INJEX-Equidyne Systems 16
4.1.1 Company Overview 16
4.2 Bioject Medical Technologies Inc 16
4.2.1 Company Overview 16
4.3 Antares Pharma Inc 16
4.3.1 Company Overview 16
4.4 PharmaJet Inc 16
4.4.1 Company Overview 16
4.5 MK Global Co. 16
4.5.1 Company Overview 16
5 Needle Free Injections Market Pipeline Products 17
6 Financial Deals Landscape 18
6.1 Debt Offerings 18
6.1.1 Merck Raises USD544 Million in Public Offering of 1.375% Notes Due 2036 18
6.1.2 Merck Raises USD544 Million in Public Offering of 0.5% Notes Due 2024 20
6.2 Equity Offerings 22
6.2.1 Valeritas Files Registration Statement for IPO for up to USD50 Million 22
6.3 Partnerships 24
6.3.1 PharmaJet Enters into Agreement with Serum Institute of India 24
6.4 Venture Financing 25
6.4.1 Pharmajet Raises USD3 Million in Venture Financing 25
6.4.2 Enable Injections Raises USD30 Million in Series A Financing 26
6.4.3 QuiO Technologies Raises USD1.05 Million in Seed Financing 28
6.4.4 Enable Injections Raises USD10 Million in Venture Financing 29
7 Recent Developments 30
7.1 Corporate Communications 30
7.1.1 Jun 06, 2017: Valeritas Appoints Peter J. Devlin to Chairman of its Board of Directors 30
7.1.2 Apr 10, 2017: Dr. John H. Noseworthy Nominated to Stand for Election to Merck Board of Directors 30
7.1.3 Apr 06, 2017: Merck Receives 2017 ENERGY STAR Sustained Excellence Award from U. S. Environmental Protection Agency 30
7.1.4 Feb 08, 2017: Baxter Appoints Dr. Stephen Oesterle to Its Board 31
7.1.5 Jan 05, 2017: Zogenix Announces CFO Transition 31
7.1.6 Nov 30, 2016: Valeritas Elects Joe Mandato, Ph.D., Experienced Medical Device Executive and Investor, to Board of Directors 32
7.1.7 Nov 17, 2016: OSE Immunotherapeutics announces the online publication of positive Phase 1 clinical results with FR104 in the Journal of Immunology 33
7.1.8 Nov 15, 2016: Oncoceutics Presents Abstracts on ONC201 at 2016 American Society of Hematology Meeting 34
7.1.9 Nov 14, 2016: Olympus VISERA 4K UHD Receives "Excellence in Surgical Products Awards," Minimally Invasive Surgical Product Category 35
7.1.10 Oct 31, 2016: Antares Pharma Appoints Fred M. Powell, Senior Vice President and Chief Financial Officer 35
7.1.11 Oct 10, 2016: Professor Ian Meredith To Join Boston Scientific As Executive Vice President And Global Chief Medical Officer 36
7.1.12 Sep 22, 2016: Industry Veteran Katherine D. Crothall, PhD to Join Valeritas Board of Directors 37
7.1.13 Aug 16, 2016: Valeritas Appoints Erick J. Lucera as Chief Financial Officer 37
7.1.14 Jul 13, 2016: Boston Scientific Elects Yoshiaki Fujimori to Board of Directors 38
7.1.15 Jul 13, 2016: Valeritas Appoints Brian K. Roberts to its Board of Directors 38
7.2 Financial Announcements 39
7.2.1 May 15, 2017: Aradigm Announces First Quarter 2017 Financial Results 39
7.2.2 May 12, 2017: Valeritas Reports First Quarter 2017 Financial Results 39
7.2.3 May 10, 2017: ICU Medical Announces First Quarter 2017 Results 40
7.2.4 May 09, 2017: Antares Pharma Reports First Quarter 2017 Operating and Financial Results 40
7.2.5 May 04, 2017: Zogenix Reports First Quarter 2017 Financial Results 42
7.2.6 May 02, 2017: Merck Announces First-Quarter 2017 Financial Results 42
7.2.7 Apr 27, 2017: Boston Scientific Announces Results For First Quarter 2017 43
7.2.8 Apr 26, 2017: Baxter Reports First-Quarter 2017 Results and Increases Financial Outlook for Full-Year 2017 44
7.2.9 Mar 28, 2017: Aradigm Announces Fourth Quarter 2016 and Full Year Financial Results 46
7.2.10 Mar 14, 2017: Antares Pharma Reports Fourth Quarter and Full Year 2016 Operating and Financial Results 47
7.2.11 Mar 09, 2017: Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results 48
7.2.12 Mar 01, 2017: ICU Medical Announces Fourth Quarter and Fiscal Year 2016 Results 49
7.2.13 Feb 21, 2017: Valeritas Reports Fourth Quarter and Full Year 2016 Financial Results 50
7.2.14 Feb 02, 2017: Boston Scientific Announces Results For Fourth Quarter And Full Year Ended December 31, 2016 51
7.2.15 Feb 02, 2017: Merck Announces Fourth-Quarter and Full-Year 2016 Financial Results 52
7.2.16 Feb 01, 2017: Baxter Reports 2016 Fourth-Quarter and Full-Year Results 53
7.2.17 Nov 10, 2016: Valeritas Reports Third Quarter 2016 Financial Results 55
7.2.18 Nov 09, 2016: Antares Pharma Reports Third Quarter 2016 Financial and Operating Results 56
7.2.19 Nov 09, 2016: Aradigm Announces Third Quarter 2016 Financial Results 57
7.2.20 Nov 09, 2016: ICU Medical Announces Third Quarter 2016 Results 58
7.2.21 Nov 08, 2016: Zogenix Provides Corporate Update and Reports Third Quarter 2016 Financial Results 59
7.2.22 Oct 26, 2016: Boston Scientific Announces Results For Third Quarter 2016 60
7.2.23 Oct 25, 2016: Baxter Reports Third Quarter 2016 Results and Increases Financial Outlook For Full-Year 2016 61
7.2.24 Oct 25, 2016: Merck Announces Third-Quarter 2016 Financial Results 62
7.2.25 Aug 10, 2016: Aradigm Announces Second Quarter 2016 Financial Results 65
7.2.26 Aug 10, 2016: Valeritas Reports Second Quarter 2016 Financial Results 66
7.2.27 Aug 09, 2016: Antares Pharma Reports Second Quarter 2016 Operating and Financial Results 66
7.2.28 Aug 09, 2016: Zogenix Provides Corporate Update and Reports Second Quarter 2016 Financial Results 68
7.2.29 Aug 08, 2016: ICU Medical Announces Second Quarter 2016 Results 69
7.2.30 Jul 28, 2016: Boston Scientific Announces Results For Second Quarter 2016 69
7.2.31 Jul 26, 2016: Baxter Reports Second Quarter 2016 Results and Raises Financial Outlook for Full-Year 2016 71
7.3 Government and Public Interest 72
7.3.1 Mar 31, 2017: City Of Austin Announces Merck Economic Development Proposal 72
7.3.2 Sep 27, 2016: Orange County Business Council Study Showcases Economic Impact of Allergan on California Economy 72
7.4 Legal And Regulatory 73
7.4.1 Dec 22, 2016: Teva Pharmaceutical Paying $519 Million to Settle FCPA Charges 73
7.4.2 Nov 17, 2016: New Data from Global aHUS Registry Presented at ASN 2016 Show a Three-Fold Reduction in Post-Transplant Dialysis in Patients Initiating Soliris (eculizumab) Treatment Prior to Transplant Compared to Initiating Treatment Post-Transplant 73
7.5 Other Significant Developments 75
7.5.1 Jun 27, 2017: Boston Scientific Outlines Strategy for Sustained Growth at 2017 Investor Day 75
7.5.2 Jan 25, 2017: Daktari Achieves Milestone in Its Merck HCV Collaboration 77
7.5.3 Jul 15, 2016: PhRMA Welcomes Five New Member Companies 77
8 Appendix 78
8.1 Research Methodology 79
8.1.1 Coverage 79
8.1.2 Secondary Research 79
8.1.3 Primary Research 80
8.1.4 Company Share Analysis 80
8.1.5 Distribution Share Analysis 80
8.1.6 Benchmarking 81
8.2 GlobalData Consulting 81
8.3 Contact Us 82
8.4 Disclaimer 82
List of Figure
1.2 List of Figures
Figure 1: Needle Free Injections Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 8
Figure 2: Needle Free Injections Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 9
Figure 3: Needle Free Injections Market, United States, Volume (Units), Historic, 2009-2016 10
Figure 4: Needle Free Injections Market, United States, Volume (Units), Forecast, 2016-2023 11
Figure 5: Needle Free Injections Market, United States, Company Share (%) 2016 14
List of Table
1.1 List of Tables
Table 1: Needle Free Injections Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 8
Table 2: Needle Free Injections Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 9
Table 3: Needle Free Injections Market, United States, Volume (Units), Historic, 2009-2016 10
Table 4: Needle Free Injections Market, United States, Volume (Units), Forecast, 2016-2023 11
Table 5: Needle Free Injections Market, United States, Average Price ($), Historic, 2009-2016 12
Table 6: Needle Free Injections Market, United States, Average Price ($), Forecast, 2016-2023 12
Table 7: Needle Free Injections Market, United States, Distribution Share by Revenue ($m), USD Constant, 2015-2016 13
Table 8: Needle Free Injections Market, United States, Company Share by Revenue ($m), USD Constant, 2016 15
Table 9: Needle Free Injections Market Pipeline Products 17
Table 10: Merck Raises USD544 Million in Public Offering of 1.375% Notes Due 2036 18
Table 11: Merck Raises USD544 Million in Public Offering of 0.5% Notes Due 2024 20
Table 12: Valeritas Files Registration Statement for IPO for up to USD50 Million 22
Table 13: PharmaJet Enters into Agreement with Serum Institute of India 24
Table 14: Pharmajet Raises USD3 Million in Venture Financing 25
Table 15: Enable Injections Raises USD30 Million in Series A Financing 26
Table 16: QuiO Technologies Raises USD1.05 Million in Seed Financing 28
Table 17: Enable Injections Raises USD10 Million in Venture Financing 29
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.